Exhibit 107
Calculation of Filing Fee Tables
SCHEDULE 14A
(Form Type)
Coeptis Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
Security Type | Security Class Title | Fee Calculation or Carry Forward Rule | Amount Registered | Proposed Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | Carry Forward Form Type | Carry Forward File Number | Carry date | Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward | |
Newly Registered Securities | ||||||||||||
Fees to Be Paid | Equity | Common | Fee Calculation | 10.22 per share | $175,000,000 |
0.0000927
| $16,222.50 | |||||
Fees Previously Paid | --- | -- | -- | -- | -- | -- | -- | |||||
Carry Forward Securities | ||||||||||||
Carry Forward Securities | -- | -- | -- | -- | -- |
-- | -- | -- | -- | -- | ||
Total Offering Amounts | $175,000,000 | $16,222.50 | ||||||||||
Total Fees Previously Paid | -- | |||||||||||
Total Fee Offsets | -- | |||||||||||
Net Fee Due | $16,222.50 |
(1) | In accordance with Rule 0-11 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) the maximum number of securities of Coeptis Therapeutics, Inc. (the “Company”) to which this transaction applies is estimated, as of September 12 2022, to be 49,477,613, which includes 41,477,613 shares of Company common stock and 8,000,000 unissued shares that underlie 8,000 issued shares of Series B Convertible Preferred Stock convertible within 60 days of the date of this proxy statement, of which it is estimated that there would be 22,239,702 shares of the Company Common Stock issued and outstanding immediately following the consummation of the Business Combination in the “no redemption” scenario, and 19,641,677 shares of the Company Common Stock issued and outstanding immediately following the consummation of the Business Combination in the “maximum redemption” scenario. |
(2) | In accordance with Exchange Act Rule 0-11, the proposed maximum aggregate value of the transaction estimated solely for the purposes of calculating the filing fee was calculated, as of September 15, 2022, based on the value of the securities and other property to be transferred to the Company security holders at the Closing of the Business Combination. |
(3) | In accordance with Section 14(g) of the Exchange Act and Exchange Act Rule 0-11, the filing fee was determined by multiplying the proposed maximum aggregate value of the transaction in note (2) above by 0.0000927. |
Table 2 – Fee Offset Claims and Sources
Registrant or Filer Name | Form or Filing Fee Type | File Number | Initial Filing Date | Fee Offset Claimed | Fee Paid with Offset Sources | |
Fee Offset Claims | -- | -- | -- | --- | -- | -- |
Fee Offset Sources | -- | -- | -- | -- | -- |